Editorial note: this article summarises published research on Dihexa and the compounds sold as Adamax. Baclabs does not sell these compounds or any peptide; we supply bacteriostatic water and reconstitution consumables. Nothing here is medical advice.
Dihexa and “Adamax” are marketed as advanced brain compounds, synaptogenic agents promising memory gains beyond what the classic nootropic peptides offer. The reality is more sobering. Dihexa has a defined mechanism and a body of rodent literature, but that literature is dominated by one laboratory and now carries a formal retraction, and there are no human trials of the compound itself. “Adamax” is not a research chemical with its own science at all; it is a vendor coinage. This article separates the two and sets out what can and cannot be supported.
Anyone searching for a “dihexa peptide protocol for memory” should read the evidence section first: the honest answer is that no validated human protocol exists.
What Dihexa is
Dihexa is N-hexanoic-Tyr-Ile-(6)aminohexanoic amide, a small molecule derived from angiotensin IV (a fragment of the angiotensin II peptide). It was engineered specifically to overcome the pharmacokinetic weaknesses of its parent: chemical modifications increased hydrophobicity and reduced hydrogen bonding, producing an orally active, blood-brain-barrier-permeant, metabolically stabilised analogue [1]. Strictly it is a peptidomimetic rather than a conventional peptide, which is why it is sometimes described as orally dosed while true peptides are not.
The proposed mechanism: HGF and c-Met
The angiotensin IV system was linked to learning after a receptor for the peptide was identified in the hippocampus, and early rodent work showed an angiotensin IV analogue could attenuate scopolamine-induced spatial learning deficits [2]. Dihexa’s proposed action narrows this to a growth-factor pathway: it is reported to potentiate hepatocyte growth factor (HGF) signalling through its receptor c-Met, augmenting HGF-dependent c-Met phosphorylation and driving dendritic branching and synapse formation [3]. HGF/c-Met is a legitimate neurotrophic target, it is the same system behind the clinical-stage drug fosgonimeton, so the hypothesis is not fringe. The question is whether the specific Dihexa data hold up.
The retraction and research-integrity problem
Much of the Dihexa mechanism rests on work from the Washington State University group of Joseph Harding and John Wright and their collaborators, including Leen Kawas. That body of work is now compromised. Four of the group’s Journal of Pharmacology and Experimental Therapeutics papers on angiotensin IV analogues received expressions of concern over possible image manipulation, an episode tied to a university misconduct inquiry into the underlying doctoral research [4]. The pivotal 2014 paper establishing the HGF/c-Met mechanism was subsequently retracted in 2025 [5].
This matters directly for anyone weighing Dihexa. When the central mechanistic paper is retracted for image manipulation, the confident claims built on it lose their foundation. The compound may still act as proposed, but the published basis for believing so is weaker than the marketing implies.
The clinical relative: fosgonimeton
The nearest thing to human evidence is not Dihexa but fosgonimeton (ATH-1017), a small-molecule HGF/MET positive modulator developed by Athira Pharma and described as a prodrug related to this chemistry. It reached late-stage trials. In September 2024, the phase 2/3 LIFT-AD study in 312 patients with mild-to-moderate Alzheimer’s disease, 40 mg given subcutaneously once daily, missed its primary endpoint, a global statistical test of cognition and function, with a non-significant result (p=0.70) [6]. In other words, the most rigorously tested drug in this mechanistic family did not show a clinical benefit. That is important context for extrapolations about Dihexa in healthy people.
Dihexa dosing and the “protocol for memory” question
Reported figures come from animal studies, not human protocols. The rodent literature used Dihexa at microgram-level doses to reverse learning deficits, and mouse Alzheimer’s-model work reported cognitive rescue via PI3K/AKT signalling. There is no established human dose, no controlled human safety data and no validated dihexa peptide protocol for memory. Vendor “protocols” circulating online are not derived from clinical evidence. Given that c-Met signalling is implicated in tumour growth and metastasis, chronic potentiation of this pathway carries a theoretical oncological risk that has not been characterised in people, an unknown that should weigh heavily.
What “Adamax” actually is
“Adamax” is where care is most needed, because it is not an established research compound. It is a vendor product, described online as a designer analogue of Semax, the Semax core sequence with an N-terminal acetyl cap, a C-terminal amide and, in one version, a P021-style adamantyl-glycine modification intended to improve blood-brain-barrier penetration. We could find no peer-reviewed studies of “Adamax” under that name. Its plausibility is borrowed entirely from Semax and from the better-researched compound P021, a separate CNTF-derived neurotrophic peptide.
The vendor labelling compounds the problem. “Adamax” is sold under two different molecular weights that are not the same molecule:
| Label | Described structure | Adamantane modification | Peer-reviewed data |
|---|---|---|---|
| Adamax-984Da | Acetylated Semax core extended with Ala-Gly (Ac-MEHFPGPAG-OH) | None | None found |
| Adamax-1032Da | Semax core with acetyl cap, C-terminal amide and P021-style adamantyl-glycine | Present | None found |
The 984 Da version lacks the adamantane group that is meant to be the whole point of the compound; on the vendors’ own descriptions, removing it produces a different molecule. Buyers ordering “Adamax” may therefore receive materially different substances depending on the supplier, with no published characterisation of either. Treat both Adamax-984Da and Adamax-1032Da as uncharacterised vendor products rather than studied drugs.
Reconstitution and diluent
Dihexa’s engineered hydrophobicity means it is poorly water-soluble, which is one reason vendors supply it in various solvent systems rather than as a simple water-reconstituted powder, a further sign that generic peptide reconstitution advice does not transfer cleanly. Where a genuine peptide is supplied as lyophilised powder for a preserved multi-dose vial, Baclabs supplies UK-stocked bacteriostatic water in 30 mL vials, and the reconstitution guide shows the concentration maths. For diluent choice see bacteriostatic versus sterile water, and for the broader group the cognitive peptides pillar and the Semax and Selank comparison.
Frequently asked questions
Does Dihexa work for memory?
Dihexa improved learning in rodent models via the HGF/c-Met pathway, but the pivotal mechanistic paper was retracted in 2025 for image manipulation, and there are no human trials of Dihexa [3][5]. The related clinical drug fosgonimeton missed its primary endpoint in a large Alzheimer’s trial [6]. There is no proven memory benefit in people.
Is there a safe Dihexa protocol?
No validated human protocol exists. Reported doses come from animal studies, and there are no controlled human safety data. Because c-Met signalling is implicated in tumour growth, chronically potentiating this pathway carries an uncharacterised theoretical cancer risk. Online “protocols” are not evidence-based.
What is the difference between Adamax-984Da and Adamax-1032Da?
They are sold under the same brand but described as different molecules. The 1032 Da version is said to carry a P021-style adamantyl-glycine modification; the 984 Da version lacks that adamantane group entirely. On the vendors’ own descriptions these are not the same compound, and neither has peer-reviewed characterisation.
Is there any published research on Adamax?
We found none under that name. “Adamax” is a vendor coinage whose plausibility is borrowed from Semax and from the separately researched peptide P021. Claims made for it are extrapolations, not findings from studies of the compound itself.
Are Dihexa and Adamax legal in the UK?
Neither holds a UK marketing authorisation, so neither can be sold or supplied as a medicine under the Human Medicines Regulations 2012 [7]. Sold as “research chemicals,” they fall outside the licensed system, with no regulated quality, purity or safety oversight.
References
- Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther, 2013
- Attenuation of scopolamine-induced spatial learning impairments by an angiotensin IV analog. Neurobiol Learn Mem, 1998
- The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the HGF/c-Met system. J Pharmacol Exp Ther, 2014 (retracted)
- Four papers by Athira CEO earn expressions of concern. Retraction Watch, 2021
- Retraction notice: The procognitive and synaptogenic effects of angiotensin IV-derived peptides…. J Pharmacol Exp Ther, 2025
- Athira Pharma topline results, phase 2/3 LIFT-AD trial of fosgonimeton. GlobeNewswire, 2024
- The Human Medicines Regulations 2012, regulation 46. legislation.gov.uk
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Bacteriostatic water is supplied for reconstitution of substances intended for research and for use as directed by a healthcare professional. Peptides and medicines discussed here may be unlicensed in the UK or prescription-only; consult a qualified clinician before using any medicine. Baclabs does not sell peptides.